Publikationen in Zusammenarbeit mit Forschern von Centro de Investigacion Biomedica en Red de Salud Mental (23)

2024

  1. The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

    EMBO Molecular Medicine, Vol. 16, Núm. 4, pp. 755-783

2023

  1. Evaluation of Sensorimotor Gating Deficits in Mice Through Prepulse Inhibition (PPI) of the Startle Response

    Methods in molecular biology (Clifton, N.J.), Vol. 2687, pp. 57-64

  2. Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects

    Molecular Neurobiology, Vol. 60, Núm. 8, pp. 4472-4487

  3. Selective inhibition of cannabinoid CB1 receptor-evoked signalling by the interacting protein GAP43

    Neuropharmacology, Vol. 240

2022

  1. Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients

    Addiction Biology, Vol. 27, Núm. 6

  2. Molecular mechanisms underlying cannabis-induced risk of psychosis

    Cannabis and the Developing Brain (Elsevier), pp. 197-242

2021

  1. Identification of bip as a cb1 receptor-interacting protein that fine-tunes cannabinoid signaling in the mouse brain

    Journal of Neuroscience, Vol. 41, Núm. 38, pp. 7924-7941

  2. Serotonin 2A receptors and cannabinoids

    Progress in Brain Research (Elsevier B.V.), pp. 135-175

2020

  1. Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia

    Frontiers in Pharmacology, Vol. 11

2019

  1. Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, Núm. 9, pp. 3863-3872

  2. Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α2-adrenoceptors in the rat frontal cortex but not locus coeruleus

    Neuropharmacology, Vol. 158

  3. Erratum: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (Proceedings of the National Academy of Sciences of the United States of America (2019) 116 (3863–3872) DOI: 10.1073/pnas.1815034116)

    Proceedings of the National Academy of Sciences of the United States of America

2018

  1. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway

    Neuropsychopharmacology, Vol. 43, Núm. 10, pp. 2028-2035

  2. The endocannabinoid system in mental disorders: Evidence from human brain studies

    Biochemical Pharmacology, Vol. 157, pp. 97-107

2017

  1. Docosahexaenoic Acid Reduces Cerebral Damage and Ameliorates Long-Term Cognitive Impairments Caused by Neonatal Hypoxia–Ischemia in Rats

    Molecular Neurobiology, Vol. 54, Núm. 9, pp. 7137-7155

  2. The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia

    European Neuropsychopharmacology, Vol. 27, Núm. 2, pp. 180-191

2016

  1. Biased agonism of three different cannabinoid receptor agonists in mouse brain cortex

    Frontiers in Pharmacology, Vol. 7, Núm. NOV

  2. Effect of subchronic corticosterone administration on α2-adrenoceptor functionality in rat brain: an in vivo and in vitro study

    Psychopharmacology, Vol. 233, Núm. 23-24, pp. 3861-3867

2015

  1. Dynamics of expression and localization of the cannabinoid system in granulosa cells during oocyte nuclear maturation

    Fertility and Sterility, Vol. 104, Núm. 3, pp. 753-760

  2. Pretreatment with resveratrol prevents neuronal injury and cognitive deficits induced by perinatal hypoxia-ischemia in rats

    PLoS ONE, Vol. 10, Núm. 11